These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
628 related articles for article (PubMed ID: 27410923)
21. Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning. Kobbe G; Schneider P; Aivado M; Zohren F; Schubert D; Fenk R; Neumann F; Kronenwett R; Pape H; Rong A; Royer-Pokora B; Hildebrandt B; Germing U; Gattermann N; Heyll A; Haas R Exp Hematol; 2002 Nov; 30(11):1346-53. PubMed ID: 12423689 [TBL] [Abstract][Full Text] [Related]
22. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264 [TBL] [Abstract][Full Text] [Related]
23. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia. Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716 [TBL] [Abstract][Full Text] [Related]
24. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study. Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556 [TBL] [Abstract][Full Text] [Related]
25. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center. Huang X; Liu D Clin Transpl; 2011; ():237-45. PubMed ID: 22755417 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Locatelli F; Bernardo ME; Bertaina A; Rognoni C; Comoli P; Rovelli A; Pession A; Fagioli F; Favre C; Lanino E; Giorgiani G; Merli P; Pagliara D; Prete A; Zecca M Lancet Oncol; 2017 Aug; 18(8):1126-1136. PubMed ID: 28705454 [TBL] [Abstract][Full Text] [Related]
27. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946 [TBL] [Abstract][Full Text] [Related]
28. Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation. Marini C; Brissot E; Bazarbachi A; Duléry R; Sestili S; Battipaglia G; Médiavilla C; Paviglianiti A; Belhocine R; Isnard F; Lapusan S; Adaeva R; Bannet A; van de Wiegert Z; Vekhoff A; Ledraa T; Legrand O; Labopin M; Bonnin A; Ruggeri A; Malard F; Mohty M Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):377-382. PubMed ID: 32234295 [TBL] [Abstract][Full Text] [Related]
29. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy. Talmadge JE Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168 [TBL] [Abstract][Full Text] [Related]
30. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958 [TBL] [Abstract][Full Text] [Related]
32. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Introna M; Borleri G; Conti E; Franceschetti M; Barbui AM; Broady R; Dander E; Gaipa G; D'Amico G; Biagi E; Parma M; Pogliani EM; Spinelli O; Baronciani D; Grassi A; Golay J; Barbui T; Biondi A; Rambaldi A Haematologica; 2007 Jul; 92(7):952-9. PubMed ID: 17606446 [TBL] [Abstract][Full Text] [Related]
33. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882 [TBL] [Abstract][Full Text] [Related]
34. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313 [TBL] [Abstract][Full Text] [Related]
35. Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies. Brierley CK; Jones FM; Hanlon K; Peniket AJ; Hatton C; Collins GP; Schuh A; Medd P; Clark A; Ward J; Chaganti S; Malladi R; Parker A; Craddock C; Danby R; Rocha V Br J Haematol; 2019 Feb; 184(4):547-557. PubMed ID: 30467838 [TBL] [Abstract][Full Text] [Related]
36. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation. Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768 [TBL] [Abstract][Full Text] [Related]